Literature DB >> 21887579

Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model.

Anna Lena Sander1, Heike Jakob, Katharina Sommer, Christian Sadler, Ingrid Fleming, Ingo Marzi, Johannes Frank.   

Abstract

PURPOSE: Epoxyeicosatrienoic acids (EETs) are known to modulate proliferation and angiogenesis in vitro. Tissue levels of EETs are regulated by the cytochrome P450 (CYP) epoxygenases that generate them as well as by the soluble epoxide hydrolase metabolizes them to their less active diols. The aim of this study was to determine the effect of locally administered EETs (11,12- and 14,15-EETs) and the selective sEH inhibitor (sEHI) trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB) on wound healing in vivo.
METHODS: Standardized full thickness dermal wounds were created on the dorsum of hairless mouse ears. Wound epithelialization was directly viewed and measured using intravitalmicroscopy and computerized planimetry every second day until healing was complete. Wound sections were analyzed by immunostaining for endothelial lineage marker CD31, vascular endothelial growth factor (VEGF), and angiogenic cytokine stromal cell-derived factor (SDF) 1α on days 2, 4, and 13.
RESULTS: Treatment with EETs and t-AUCB, respectively, significantly accelerated wound epithelialization and neovascularization by synergistic upregulation of SDF1α and VEGF in vivo.
CONCLUSIONS: These findings demonstrated that exogenous CYP-derived EETs and globally decreased EET hydrolysis by sEH inhibition significantly accelerated wound epithelialization and neovascularization in unimpaired healing wounds. Given that hypoxia induces CYP expression and subsequently EET-dependent angiogenesis, EETs and sEHIs provide a promising new class of therapeutics for ischemic non-healing wounds.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21887579     DOI: 10.1007/s00423-011-0838-z

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  42 in total

1.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

Review 2.  Hydroxylation of HIF-1: oxygen sensing at the molecular level.

Authors:  Gregg L Semenza
Journal:  Physiology (Bethesda)       Date:  2004-08

3.  The hairless mouse ear: an in vivo model for studying wound neovascularization.

Authors:  J H Barker; D Kjolseth; M Kim; J Frank; I Bondar; E Uhl; M Kamler; K Messmer; G R Tobin; L J Weiner
Journal:  Wound Repair Regen       Date:  1994 Mar-Apr       Impact factor: 3.617

4.  Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release.

Authors:  D H Munzenmaier; D R Harder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-04       Impact factor: 4.733

5.  Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells.

Authors:  Meetha Medhora; John Daniels; Kavita Mundey; Beate Fisslthaler; Rudi Busse; Elizabeth R Jacobs; David R Harder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09-26       Impact factor: 4.733

6.  Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4.

Authors:  Anke C Webler; Rüdiger Popp; Thomas Korff; U Ruth Michaelis; Carmen Urbich; Rudi Busse; Ingrid Fleming
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-13       Impact factor: 8.311

7.  Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.

Authors:  In-Hae Kim; Christophe Morisseau; Takaho Watanabe; Bruce D Hammock
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

8.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

9.  Biphasic expression of stromal cell-derived factor-1 during human wound healing.

Authors:  A Toksoy; V Müller; R Gillitzer; M Goebeler
Journal:  Br J Dermatol       Date:  2007-10-17       Impact factor: 9.302

10.  Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells.

Authors:  U Ruth Michaelis; Ning Xia; Eduardo Barbosa-Sicard; John R Falck; Ingrid Fleming
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03       Impact factor: 4.799

View more
  15 in total

1.  Cytochrome P450 (CYP) epoxygenases as potential targets in the management of impaired diabetic wound healing.

Authors:  Huichen Zhao; Jicui Chen; Jiachao Chai; Yuchao Zhang; Cong Yu; Zhe Pan; Peng Gao; Chen Zong; Qingbo Guan; Yuqin Fu; Yuantao Liu
Journal:  Lab Invest       Date:  2017-03-20       Impact factor: 5.662

2.  Inhibition of soluble epoxide hydrolase augments astrocyte release of vascular endothelial growth factor and neuronal recovery after oxygen-glucose deprivation.

Authors:  Yue Zhang; Gina Hong; Kin Sing Stephen Lee; Bruce D Hammock; Debebe Gebremedhin; David R Harder; Raymond C Koehler; Adam Sapirstein
Journal:  J Neurochem       Date:  2017-01-23       Impact factor: 5.372

3.  Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis.

Authors:  Guang-Yu Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-16       Impact factor: 11.205

4.  Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.

Authors:  Yann Savina; Thomas Duflot; Frederic Bounoure; Sylvain Kotzki; Pierre-Alain Thiebaut; Pierre-Alex Serreau; Mohamed Skiba; Jean-Michel Picquenot; Marie Cornic; Christophe Morisseau; Bruce Hammock; Laurent Imbert; Jean-Luc Cracowski; Vincent Richard; Matthieu Roustit; Jeremy Bellien
Journal:  Diab Vasc Dis Res       Date:  2019-07-03       Impact factor: 3.291

Review 5.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

6.  Epoxyeicosanoids promote organ and tissue regeneration.

Authors:  Dipak Panigrahy; Brian T Kalish; Sui Huang; Diane R Bielenberg; Hau D Le; Jun Yang; Matthew L Edin; Craig R Lee; Ofra Benny; Dayna K Mudge; Catherine E Butterfield; Akiko Mammoto; Tadanori Mammoto; Bora Inceoglu; Roger L Jenkins; Mary A Simpson; Tomoshige Akino; Fred B Lih; Kenneth B Tomer; Donald E Ingber; Bruce D Hammock; John R Falck; Vijaya L Manthati; Arja Kaipainen; Patricia A D'Amore; Mark Puder; Darryl C Zeldin; Mark W Kieran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

Review 7.  Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer.

Authors:  Guodong Zhang; Sean Kodani; Bruce D Hammock
Journal:  Prog Lipid Res       Date:  2013-12-15       Impact factor: 16.195

8.  Inhibition of Soluble Epoxide Hydrolase 2 Ameliorates Diabetic Keratopathy and Impaired Wound Healing in Mouse Corneas.

Authors:  Haijing Sun; Patrick Lee; Chenxi Yan; Nan Gao; Jiemei Wang; Xianqun Fan; Fu-Shin Yu
Journal:  Diabetes       Date:  2018-04-03       Impact factor: 9.461

Review 9.  Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.

Authors:  Bei Wang; Lujin Wu; Jing Chen; Lingli Dong; Chen Chen; Zheng Wen; Jiong Hu; Ingrid Fleming; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2021-02-26

10.  Genetic deletion of soluble epoxide hydrolase attenuates inflammation and fibrosis in experimental obstructive nephropathy.

Authors:  Chin-Wei Chiang; Hsueh-Te Lee; Der-Cherng Tarng; Ko-Lin Kuo; Li-Ching Cheng; Tzong-Shyuan Lee
Journal:  Mediators Inflamm       Date:  2015-01-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.